Analysis of genetic alterations and clonal proliferation in children treated for acute lymphocytic leukemia

Cancer Research

Volumn 66, Issue 17, 2006, Pages 8455-8461

  Kendall, Heather E ^a,b   Vacek, Pamela M ^b   Rivers, Jami L ^b   Rice, Sederick C ^a   Messier, Terri L ^a,b   Finette, Barry A ^a,b  

^a UNIVERSITY OF VERMONT   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; T LYMPHOCYTE RECEPTOR;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CANCER SURVIVOR; CELL MUTANT; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; MALE; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SOMATIC CELL; T LYMPHOCYTE;

ANTINEOPLASTIC AGENTS; BURKITT LYMPHOMA; CHILD; CHILD, PRESCHOOL; CLONING, MOLECULAR; FEMALE; HUMANS; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MALE; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ANTIGEN, T-CELL;

EID: 33748999035     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4015     Document Type: Article

References (33)

1. Gloeckler-Ries LA, Smith MA, Gurney JG, et al. Cancer incidence and survival among children and adolescents: United States SEER Program, 1975-1995. Bethesda (MD): National Cancer Institute; 1999. Report No.: SEER Program. NIH Pub. No. 99-4649.
2. Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukaemia-current status and future perspectives. Lancet Oncol 2001;2:597-607.
3. Stahnke K, Fulda S, Friesen C, Straub G, Debatin K-M. Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy. Blood 2001;98:3066-73.
4. Friedman DL, Meadows AT. Late effects of childhood cancer therapy. Pediatr Clin North Am 2002;49:1083-106, x.
5. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst 2001;93:618-29.
6. Finette BA, Homans AC, Albertini RJ. Emergence of genetic instability in children treated for leukemia. Science 2000;288:514-7.
7. Rice SC, Vacek P, Homans AH, et al. Genotoxicity of therapeutic intervention in children with acute lymphocytic leukemia. Cancer Res 2004;64:4464-71.
8. Finette BA, Sullivan LM, O'Neill JP, Nicklas JA, Vacek PM, Albertini RJ. Determination of HPRT mutant frequencies in T-lymphocytes from a healthy pediatric population: statistical comparison between newborn, children and adult mutant frequencies, cloning efficiency and age. Mutat Res 1994;308:223-31.
9. Messier T, O'Neill JP, Hou S-M, Nicklas JA, Finette BA. In vivo transposition mediated by V(D)J recombinase in human T-lymphocytes. EMBO J 2003;22:1381-8.
10. Gibbs RA, Nguyen P-N, Edwards A, Civitello AB, Caskey CT. Multiplex DNA deletion detection and exon sequencing of the hypoxanthine phosphoribosyltransferase gene in Lesch-Nyhan families. Genomics 1990;7:235-44.
11. Finette BA, Poseno T, Albertini RJ. V(D)J recombinase-mediated HPRT mutations in peripheral blood lymphocytes of normal children. Cancer Res 1996;56:1405-12.
12. Fuscoe JC, Zimmerman LJ, Lippert MJ, Nicklas JA, O'Neill JP, Albertini RJ. V(D)J recombinase-like activity mediates hprt gene deletion in human fetal T-lymphocytes. Cancer Res 1991;51:6001-5.
13. Finette BA, Homans AC, Rivers J, Messier T, Albertini RJ. Accumulation of somatic mutations in proliferating T cell clones from children treated for leukemia. Leukemia 2001;15:1898-905.
14. Nicklas JA, O'Neill JP, Albertini RJ. Use of T-cell receptor gene probes to quantify the in vivo hprt mutations in human T-lymphocytes. Mutat Res 1986;173:65-72.
15. Abramson LS, Albertini RJ, Pachman LM, Finette BA. Association among somatic HPHT mutant frequency, peripheral blood T-lymphocyte clonality, and serologic parameters of disease activity in children with juvenile onset dermatomyositis. Clin Immunol 1999;91:61-7.
16. Burkhart-Schultz KJ, Thompson CL, Jones IM. Spectrum of somatic mutation at the hypoxanthine phosphoribosyltransferase (hprt) gene of healthy people. Carcinogenesis 1996;17:1871-83.
17. Finette BA, Kendall H, Vacek PM. Mutational spectral analysis at the HPRT locus in healthy children. Mutat Res 2002;505:27-41.
18. Skandalis A, Ford BN, Glickman BW. Strand bias in mutation involving 5-methylcytosine deamination in the human hprt gene. Mutat Res 1994;314:21-6.
19. Podlutsky A, Osterholm A-M, Hou S-M, Hofmaier A, Lambert B. Spectrum of point mutations in the coding region of the hypoxanthine-guanine phosporibosyltransferase (hprt) gene in human T-lymphocytes in vivo. Carcinogenesis 1998;19:557-66.
20. Rideout WM III, Coetzee GA, Olumi AF, Jones PA. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science 1990;249:1288-90.
21. Zingg J-M, Jones PA. Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis 1997;18:869-82.
22. Ek T, Mellander L, Andersson B, Abrahamsson J. Immune reconstitution after childhood acute lymphoblastic leukemia is most severely affected in the high risk group. Pediatr Blood Cancer 2005;44:461-8.
23. O'Neill JP, Finette BA. Transition mutations at CpG dinucleotides are the most frequent in vivo spontaneous single base substitution mutation in the human HPRT gene. Environ Mol Mutagen 1998;32:188-91.
24. Cooper DN, Youssoufian H. The CpG dinucleotide and human genetic disease. Hum Genet 1988;78:151-5.
25. Hsu GW, Ober M, Carell T, Beese LS. Error-prone replication of oxidatively damaged DNA by a high-fidelity DNA polymerase. Nature 2004;431:217-21.
26. Groninger E, Meeuwsen-De Boer GJ, De Graaf SS, Kamps WA, De Bont ES. Vincristine induced apoptosis in acute lymphoblastic leukaemia cells: a mitochondrial controlled pathway regulated by reactive oxygen species? Int J Oncol 2002;21:1339-45.
27. Hirota H, Kubota M, Hashimoto H, et al. Analysis of hprt gene mutation following anti-cancer treatment in pediatric patients with acute leukemia. Mutat Res 1993;319:113-20.
28. Tonegawa S. Somatic generation of antibody diversity. Nature 1983;302:575-81.
29. Yoshioka M, O'Neill JP, Vacek PM, Finette BA. Gestational age and gender specific in utero V(D)J recombinase mediated deletions. Cancer Res 2001;61:3432-8.
30. Mather EL, Perry RP. Methylation status and DNase I sensitivity of immunoglobulin genes: changes associated with rearrangement. Proc Natl Acad Sci U S A 1983;80:4689-93.
31. Storb U, Arp B. Methylation patterns of immunoglobulin genes in lymphoid cells: correlation of expression and differentiation with undermethylation. Proc Natl Acad Sci U S A 1983;80:6642-6.
32. Nyce JW. Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy. Mutat Res 1997;386:153-61.
33. Wachsman JT. DNA methylation and the association between genetic and epigenetic changes: relation to carcinogenesis. Mutat Res 1997;375:1-8.